Literature DB >> 25457459

Durability and survival are similar after elective endovascular and open repair of abdominal aortic aneurysms in younger patients.

Kevin Lee1, Elaine Tang1, Luc Dubois1, Adam H Power1, Guy DeRose1, Thomas L Forbes2.   

Abstract

OBJECTIVE: The role of endovascular repair (EVAR) of aortic aneurysms in young patients is controversial. The purpose of this study was to determine the long-term outcomes and reintervention rates in patients 60 years of age or younger who underwent elective open or endovascular repair of an abdominal aortic aneurysm.
METHODS: Retrospective review of a prospectively collected vascular surgery database at a university-affiliated medical center was performed to identify all patients who underwent elective repair of an abdominal aortic aneurysm between 2000 and 2013 and were 60 years of age or younger at the time of the repair. Preoperative anatomic measurements were performed and compared with instructions for use (IFU) criteria for the endografts.
RESULTS: The study cohort comprised 169 patients 60 years of age or younger (mean age, 56.7 ± 2.8 years) who underwent elective repair (119 open repair, 50 EVAR). Patients treated with open repair and EVAR had similar comorbidities, except that EVAR patients were more likely to have hypertension (P = .03) and poor left ventricular function (P = .04). The open repair group had significantly larger suprarenal (P = .004) and infrarenal (P = .005) neck angles, shorter neck lengths (P < .001), and larger maximum aneurysm diameter (P = .02) compared with the EVAR group. Only five patients (13%) in the EVAR group did not meet all IFU criteria. The overall in-hospital mortality rate was 1.8% (0% EVAR, 2.5% open repair; P = .56). Overall mean life expectancy was 11.5 years (9.8 years EVAR, 11.9 years open repair; P = .09). The 1-year (98% EVAR, 96% open repair), 5-year (86% EVAR, 88% open repair), and 10-year (54% EVAR, 75% open repair) survival did not differ between EVAR and open repair (P = .16). Long-term survival (78% EVAR, 85% open repair; P = .09) and reintervention rates (12% EVAR, 16% open repair; P = .80) did not differ. No late aneurysm rupture or aneurysm-related deaths were observed. The most common causes of long-term mortality were malignant disease and cardiovascular events. Reinterventions in the open repair group were exclusively laparotomy related (incisional hernia repairs), whereas all reinterventions in the EVAR group were aortic related, including one conversion to open repair.
CONCLUSIONS: After elective aneurysm repair, younger patients have a moderate life expectancy related to malignant disease and cardiovascular health. EVAR offers durability and long-term survival similar to those with open repair in these younger patients as long as aneurysm anatomy and IFU are adhered to.
Copyright © 2015 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25457459     DOI: 10.1016/j.jvs.2014.10.012

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  12 in total

1.  Fate of Aneurysmal Common Iliac Artery Landing Zones Used for Endovascular Aneurysm Repair.

Authors:  Claire L Griffin; Salvatore T Scali; Robert J Feezor; Catherine K Chang; Kristina A Giles; Javairiah Fatima; Thomas S Huber; Adam W Beck
Journal:  J Endovasc Ther       Date:  2015-08-19       Impact factor: 3.487

2.  Inferior Mid-term Durability with Comparable Survival for Younger Patients Undergoing Elective Endovascular Infrarenal versus Open Abdominal Aortic Aneurysm Repair.

Authors:  Katherine M Reitz; Nathan L Liang; Bowen Xie; Michel Makaroun; Edith Tzeng
Journal:  Ann Vasc Surg       Date:  2019-10-18       Impact factor: 1.466

3.  Comparable perioperative mortality outcomes in younger patients undergoing elective open and endovascular abdominal aortic aneurysm repair.

Authors:  Nathan L Liang; Katherine M Reitz; Michel S Makaroun; Mahmoud B Malas; Edith Tzeng
Journal:  J Vasc Surg       Date:  2017-10-31       Impact factor: 4.268

Review 4.  The Abdominal Aortic Aneurysm and Intraluminal Thrombus: Current Concepts of Development and Treatment.

Authors:  Aleksandra Piechota-Polanczyk; Alicja Jozkowicz; Witold Nowak; Wolf Eilenberg; Christoph Neumayer; Tadeusz Malinski; Ihor Huk; Christine Brostjan
Journal:  Front Cardiovasc Med       Date:  2015-05-26

5.  Is Age a Determinant Factor in EVAR as a Predictor of Outcomes or in the Selection Procedure? Our Experience.

Authors:  Rui Machado; Gabriela Teixeira; Pedro Oliveira; Luís Loureiro; Carlos Pereira; Rui Almeida
Journal:  Braz J Cardiovasc Surg       Date:  2016-04

6.  Abdominal Aortic Aneurysm Repair: Results from a Series of Young Patients.

Authors:  Pasqualino Sirignano; Francesco Speziale; Nunzio Montelione; Chiara Pranteda; Giuseppe Galzerano; Wassim Mansour; Enrico Sbarigia; Carlo Setacci
Journal:  Biomed Res Int       Date:  2016-09-29       Impact factor: 3.411

7.  Impact of chronic obstructive pulmonary disease on patients with aortic aneurysms: a nationwide retrospective cohort study in Taiwan.

Authors:  Kuang-Ming Liao; Chung-Yu Chen
Journal:  BMJ Open       Date:  2017-09-03       Impact factor: 2.692

Review 8.  A clinical and ethical review on late results and benefits after EVAR.

Authors:  Carlo Setacci; Pasqualino Sirignano; Vittorio Fineschi; Paola Frati; Giovanna Ricci; Francesco Speziale
Journal:  Ann Med Surg (Lond)       Date:  2017-02-20

9.  Outcomes over Time in Patients with Hostile Neck Anatomy Undergoing Endovascular Repair of Abdominal Aortic Aneurysm.

Authors:  Yolanda Bryce; Wonho Kim; Barry Katzen; James Benenati; Shaun Samuels
Journal:  J Vasc Interv Radiol       Date:  2018-05-31       Impact factor: 3.682

10.  Re-interventions after endovascular aortic repair for infrarenal abdominal aneurysms: a retrospective cohort study.

Authors:  Håkan Roos; Henrik Djerf; Ludvig Brisby Jeppsson; Victoria Fröjd; Tomas Axelsson; Anders Jeppsson; Mårten Falkenberg
Journal:  BMC Cardiovasc Disord       Date:  2016-06-06       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.